Association of statin use with cognitive decline in elderly African Americans

S. J. Szwast, Hugh Hendrie, K. A. Lane, Sujuan Gao, S. E. Taylor, Frederick Unverzagt, J. Murrell, M. Deeg, A. Ogunniyi, Martin Farlow, Kathleen Hall

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

BACKGROUND: Previously reported associations between statin use and incident dementia or cognitive decline have been inconsistent. We report the results from a 3-year prospective study on the association of statin use on cognitive decline and incident dementia in elderly African Americans. METHODS: A community-based cohort of 1,146 African Americans aged 70 and older living in Indianapolis, Indiana, was evaluated in 2001 and 2004. The instrument used for cognitive assessment was the Community Screening Interview for Dementia (CSI-D). Cognitive decline was defined as CSI-D scores measured at 2001 minus scores at 2004. Measurements of low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) were obtained from baseline blood samples. RESULTS: Adjusting for age at baseline, gender, education, and the possession of ApoE ε4 allele, baseline statin use was associated with less cognitive decline (p = 0.0177). There were no significant interactions of statin use when LDL-C and CRP were included. Logistic regression with the four independent variables showed that statin use may be associated with a reduction in incident dementia (OR = 0.32; p = 0.0673). Association with cognitive decline was less clear when investigating statin use over time. Significance remained only for those who discontinued prior to follow-up compared to continuous users or users who started after baseline. CONCLUSIONS: The relationship between statin use and cognitive decline is complex and subjected to unknown confounders. This effect may not be associated with the cholesterol lowering or anti-inflammatory action of statins.

Original languageEnglish
Pages (from-to)1873-1880
Number of pages8
JournalNeurology
Volume69
Issue number19
DOIs
StatePublished - Nov 2007

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
African Americans
Dementia
C-Reactive Protein
LDL Cholesterol
Interviews
Cognitive Dysfunction
Apolipoproteins E
Anti-Inflammatory Agents
Logistic Models
Alleles
Cholesterol
Prospective Studies
Education

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Association of statin use with cognitive decline in elderly African Americans. / Szwast, S. J.; Hendrie, Hugh; Lane, K. A.; Gao, Sujuan; Taylor, S. E.; Unverzagt, Frederick; Murrell, J.; Deeg, M.; Ogunniyi, A.; Farlow, Martin; Hall, Kathleen.

In: Neurology, Vol. 69, No. 19, 11.2007, p. 1873-1880.

Research output: Contribution to journalArticle

Szwast, S. J. ; Hendrie, Hugh ; Lane, K. A. ; Gao, Sujuan ; Taylor, S. E. ; Unverzagt, Frederick ; Murrell, J. ; Deeg, M. ; Ogunniyi, A. ; Farlow, Martin ; Hall, Kathleen. / Association of statin use with cognitive decline in elderly African Americans. In: Neurology. 2007 ; Vol. 69, No. 19. pp. 1873-1880.
@article{03dbad99d90643259a250919d07b41c0,
title = "Association of statin use with cognitive decline in elderly African Americans",
abstract = "BACKGROUND: Previously reported associations between statin use and incident dementia or cognitive decline have been inconsistent. We report the results from a 3-year prospective study on the association of statin use on cognitive decline and incident dementia in elderly African Americans. METHODS: A community-based cohort of 1,146 African Americans aged 70 and older living in Indianapolis, Indiana, was evaluated in 2001 and 2004. The instrument used for cognitive assessment was the Community Screening Interview for Dementia (CSI-D). Cognitive decline was defined as CSI-D scores measured at 2001 minus scores at 2004. Measurements of low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) were obtained from baseline blood samples. RESULTS: Adjusting for age at baseline, gender, education, and the possession of ApoE ε4 allele, baseline statin use was associated with less cognitive decline (p = 0.0177). There were no significant interactions of statin use when LDL-C and CRP were included. Logistic regression with the four independent variables showed that statin use may be associated with a reduction in incident dementia (OR = 0.32; p = 0.0673). Association with cognitive decline was less clear when investigating statin use over time. Significance remained only for those who discontinued prior to follow-up compared to continuous users or users who started after baseline. CONCLUSIONS: The relationship between statin use and cognitive decline is complex and subjected to unknown confounders. This effect may not be associated with the cholesterol lowering or anti-inflammatory action of statins.",
author = "Szwast, {S. J.} and Hugh Hendrie and Lane, {K. A.} and Sujuan Gao and Taylor, {S. E.} and Frederick Unverzagt and J. Murrell and M. Deeg and A. Ogunniyi and Martin Farlow and Kathleen Hall",
year = "2007",
month = "11",
doi = "10.1212/01.wnl.0000279333.77404.d7",
language = "English",
volume = "69",
pages = "1873--1880",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "19",

}

TY - JOUR

T1 - Association of statin use with cognitive decline in elderly African Americans

AU - Szwast, S. J.

AU - Hendrie, Hugh

AU - Lane, K. A.

AU - Gao, Sujuan

AU - Taylor, S. E.

AU - Unverzagt, Frederick

AU - Murrell, J.

AU - Deeg, M.

AU - Ogunniyi, A.

AU - Farlow, Martin

AU - Hall, Kathleen

PY - 2007/11

Y1 - 2007/11

N2 - BACKGROUND: Previously reported associations between statin use and incident dementia or cognitive decline have been inconsistent. We report the results from a 3-year prospective study on the association of statin use on cognitive decline and incident dementia in elderly African Americans. METHODS: A community-based cohort of 1,146 African Americans aged 70 and older living in Indianapolis, Indiana, was evaluated in 2001 and 2004. The instrument used for cognitive assessment was the Community Screening Interview for Dementia (CSI-D). Cognitive decline was defined as CSI-D scores measured at 2001 minus scores at 2004. Measurements of low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) were obtained from baseline blood samples. RESULTS: Adjusting for age at baseline, gender, education, and the possession of ApoE ε4 allele, baseline statin use was associated with less cognitive decline (p = 0.0177). There were no significant interactions of statin use when LDL-C and CRP were included. Logistic regression with the four independent variables showed that statin use may be associated with a reduction in incident dementia (OR = 0.32; p = 0.0673). Association with cognitive decline was less clear when investigating statin use over time. Significance remained only for those who discontinued prior to follow-up compared to continuous users or users who started after baseline. CONCLUSIONS: The relationship between statin use and cognitive decline is complex and subjected to unknown confounders. This effect may not be associated with the cholesterol lowering or anti-inflammatory action of statins.

AB - BACKGROUND: Previously reported associations between statin use and incident dementia or cognitive decline have been inconsistent. We report the results from a 3-year prospective study on the association of statin use on cognitive decline and incident dementia in elderly African Americans. METHODS: A community-based cohort of 1,146 African Americans aged 70 and older living in Indianapolis, Indiana, was evaluated in 2001 and 2004. The instrument used for cognitive assessment was the Community Screening Interview for Dementia (CSI-D). Cognitive decline was defined as CSI-D scores measured at 2001 minus scores at 2004. Measurements of low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) were obtained from baseline blood samples. RESULTS: Adjusting for age at baseline, gender, education, and the possession of ApoE ε4 allele, baseline statin use was associated with less cognitive decline (p = 0.0177). There were no significant interactions of statin use when LDL-C and CRP were included. Logistic regression with the four independent variables showed that statin use may be associated with a reduction in incident dementia (OR = 0.32; p = 0.0673). Association with cognitive decline was less clear when investigating statin use over time. Significance remained only for those who discontinued prior to follow-up compared to continuous users or users who started after baseline. CONCLUSIONS: The relationship between statin use and cognitive decline is complex and subjected to unknown confounders. This effect may not be associated with the cholesterol lowering or anti-inflammatory action of statins.

UR - http://www.scopus.com/inward/record.url?scp=35948977729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948977729&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000279333.77404.d7

DO - 10.1212/01.wnl.0000279333.77404.d7

M3 - Article

C2 - 17984456

AN - SCOPUS:35948977729

VL - 69

SP - 1873

EP - 1880

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 19

ER -